FDA expands regulatory use of real-world evidence with industry collaborations

Written by Darcy Hodge, Editor


As part of the FDA’s expanding trust in real-world evidence (RWE), health care technology company Aetion (NY, USA) and pharmaceutical company Cardinal Health (OH, USA) are set to work alongside the FDA to advance RWE. First, the FDA will utilize the Aetion Evidence Platform® to construct a framework and research methodology for COVID-19 inpatient devices. The move furthers the wider aims of the FDA in increasing the incorporation of digital platforms in healthcare decision-making. The platform is potentially advantageous for these aims due to the availability of efficient, transparent and reliable RWE research. Platform-based approaches have the potential to accelerate...

To view this content, please register now for access

It's completely free